Amanda Malone
Chief Operating Officer at EUPRAXIA PHARMACEUTICALS INC.
Net worth: 132 078 $ as of 2024-04-29
Amanda Malone active positions
Companies | Position | Start | End |
---|---|---|---|
EUPRAXIA PHARMACEUTICALS INC. | Chief Operating Officer | 2012-07-31 | - |
Chief Tech/Sci/R&D Officer | 2012-07-31 | - |
Career history of Amanda Malone
Former positions of Amanda Malone
Companies | Position | Start | End |
---|---|---|---|
Auritec Pharmaceuticals, Inc.
Auritec Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Part of EyePoint Pharmaceuticals, Inc., Auritec Pharmaceuticals, Inc. is a drug delivery company based in Santa Monica, CA. The company focuses on leveraging their scientific team's 20 years of experience in extended release delivery systems to overcome the challenges of drug delivery in bringing new therapies to patients. The company aims to develop bioavailable dosage forms and target drugs to their sites of action, as well as play major roles in the life-cycle management of older products. Auritec Pharmaceuticals has secured national institute of health (nih) funding for much of their work, indicating the level of expertise and the advanced state of their technology. | Chief Operating Officer | 2007-09-30 | 2014-01-31 |
Training of Amanda Malone
Stanford University | Doctorate Degree |
Harvey Mudd College | Undergraduate Degree |
Statistics
International
United States | 4 |
Canada | 2 |
Operational
Chief Operating Officer | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Undergraduate Degree | 1 |
Sectoral
Consumer Services | 3 |
Health Technology | 2 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
EUPRAXIA PHARMACEUTICALS INC. | Health Technology |
Private companies | 1 |
---|---|
Auritec Pharmaceuticals, Inc.
Auritec Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Part of EyePoint Pharmaceuticals, Inc., Auritec Pharmaceuticals, Inc. is a drug delivery company based in Santa Monica, CA. The company focuses on leveraging their scientific team's 20 years of experience in extended release delivery systems to overcome the challenges of drug delivery in bringing new therapies to patients. The company aims to develop bioavailable dosage forms and target drugs to their sites of action, as well as play major roles in the life-cycle management of older products. Auritec Pharmaceuticals has secured national institute of health (nih) funding for much of their work, indicating the level of expertise and the advanced state of their technology. | Commercial Services |
- Stock Market
- Insiders
- Amanda Malone
- Experience